-
公开(公告)号：US07572437B2
公开(公告)日：2009-08-11
申请号：US10851666
申请日：2004-05-24
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
-
Patent Agency Ranking
公开(公告)号：US20090053173A1
公开(公告)日：2009-02-26
申请号：US10851666
申请日：2004-05-24
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
Abstract translation: 为干扰素类似物提供了组合物，试剂盒和方法，以促进一般健康或治疗疾病。 人类干扰素类似物通过干扰素与人血清白蛋白的融合来制备。 生物测定显示具有相同抗细胞病毒侵袭能力的干扰素类似物在体内比干扰素具有3-10倍的作用功能。 这些新型长效干扰素类似物可用于治疗病毒感染患者，如SARS病毒，HIV，HCV，HBV或HAV，以及癌症疾病如白血病和恶性黑色素瘤。 与干扰素相比，它们的保质期还有3-5倍。
-
13.发明授权Recombinant human albumin-erythropoietin fusion proteins with long-lasting biological effects 有权重组人白蛋白促红细胞生成素融合蛋白具有持久的生物学作用公开(公告)号：US07442371B2
公开(公告)日：2008-10-28
申请号：US11825686
申请日：2007-07-08
CPC classification number: A61K38/38 , A61K47/643 , A61K47/646 , C07H21/04 , C07K14/47 , C07K14/475 , C07K14/505 , C07K14/52 , C07K14/54 , C07K14/5403 , C07K14/5431 , C07K14/765 , C07K14/79 , C07K2319/00 , Y02A50/463 , A61K2300/00
Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
Abstract translation: 提供了通过使用人血清白蛋白（HSA）和生物活性分子的新型重组融合蛋白来促进一般健康或预防或治疗疾病的组合物，试剂盒和方法。 生物活性分子可以是在体外或体内具有生物学功能的蛋白质或肽，并且优选地，当施用于人时具有治疗活性。 通过将生物活性分子融合到HSA中，可以改善体内生物活性分子的稳定性，并且由于体内毒性降低和持久的治疗效果，治疗指数增加。 此外，提供制造方法用于在酵母中有效，成本有效地生产这些重组蛋白。
-
公开(公告)号：US20060051859A1
公开(公告)日：2006-03-09
申请号：US10936447
申请日：2004-09-09
CPC classification number: C07K14/555 , C07K2319/00
Abstract: Compositions, kits and methods are provided for Interferon analogs in order to promote general health or for therapeutic treatment of diseases. Human interferon analogs are made by fusion of interferon with human serum albumin. The bio-assay shows that the interferon analogs with the same cell protection against viral attack have 3-10 times longer acting function than interferon in vivo. These novel long acting interferon analogs can be used in treatment of patients with viral infection, such as SARS virus, HIV, HCV, HBV, or HAV, and the cancer diseases, such as leukemia and malignant melanoma. They also have a 3-5 times longer shelf-life compared with interferon.
-
15.发明授权Methods for amplifying and detecting multiple polynucleotides on a solid phase support 失效在固相载体上扩增和检测多个多核苷酸的方法公开(公告)号：US06500620B2
公开(公告)日：2002-12-31
申请号：US09741983
申请日：2000-12-19
Applicant: Zailin Yu , Zaoyuan Peng , Qianjin Hu
Inventor： Zailin Yu , Zaoyuan Peng , Qianjin Hu
IPC: C12Q168
CPC classification number: C12Q1/6809 , C12Q1/6837 , C12Q1/6851 , C12Q2600/158 , C12Q2565/501 , C12Q2565/537 , C12Q2531/113
Abstract: Methods for solid phase polymerase-mediated amplification using immobilized primers on a microarray are provided for detecting and cloning multiple target polynucleotides. The methods, compositions and kits provided herein are useful for research and clinical applications, particularly for large scale assays of genetic information in biological samples of interest.
Abstract translation: 提供使用固定引物在微阵列上进行固相聚合酶介导扩增的方法用于检测和克隆多个靶多核苷酸。 本文提供的方法，组合物和试剂盒可用于研究和临床应用，特别是对于感兴趣的生物样品中遗传信息的大规模测定。
-
公开(公告)号：US06376191B1
公开(公告)日：2002-04-23
申请号：US09707366
申请日：2000-11-06
Applicant: Zailin Yu , Zaoyuan Peng , Qianjin Hu
Inventor： Zailin Yu , Zaoyuan Peng , Qianjin Hu
IPC: C12Q168
CPC classification number: C12Q1/6858 , C12Q2565/501 , C12Q2565/537
Abstract: Solid phase polymerase-mediated amplification approaches using immobilized primers on a microarray are provided for detecting sequence variations in a target polynucleotide. The methods and compositions provided herein are useful for research and clinical applications, particularly for large scale assays of genetic information in biological samples of interest.
Abstract translation: 提供使用固定引物在微阵列上的固相聚合酶介导的扩增方法，用于检测靶多核苷酸中的序列变异。 本文提供的方法和组合物可用于研究和临床应用，特别是对于感兴趣的生物样品中遗传信息的大规模测定。
-
-
-
-
-
Search Results
16
records
(took 0.018 seconds)
